Lobbying disclosures · Lobbying report
NBIX: second_quarter 2026 lobbying report
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impactin
Follow NBIX- Became public
- Jul 8, 2026, 3:17 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 4:03 PM EST
Why this is connected
Exact legal-name match: NEUROCRINE BIOSCIENCES INC (https://www.sec.gov/Archives/edgar/data/914475/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/6b16b265-23eb-4a42-b240-0a8544c3ce9b/","filing_uuid":"6b16b265-23eb-4a42-b240-0a8544c3ce9b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/6b16b265-23eb-4a42-b240-0a8544c3ce9b/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Allegra M. Han","dt_posted":"2026-07-08T15:17:12-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 13th Street NW, 2nd Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":313715,"url":"https://lda.gov/api/v1/registrants/313715/","house_registrant_id":39384,"name":"CAPITOL COUNSEL LLC","description":"Government affairs.","address_1":"700 13th Street NW, 2nd Floor","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TRACEY A. GRAY","contact_telephone":"+1 202-861-3200","dt_updated":"2026-07-31T14:55:49.985763-04:00"},"client":{"id":213200,"url":"https://lda.gov/api/v1/clients/213200/","client_id":1007871,"name":"NEUROCRINE BIOSCIENCES, INC.","general_description":"Drug discovery and development.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-12-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":60147,"prefix":null,"prefix_display":null,"first_name":"LUKE","nickname":null,"middle_name":null,"last_name":"HATZIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69294,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"EANNELLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152462,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":60147,"prefix":null,"prefix_display":null,"first_name":"LUKE","nickname":null,"middle_name":null,"last_name":"HATZIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69294,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"EANNELLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152462,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":60147,"prefix":null,"prefix_display":null,"first_name":"LUKE","nickname":null,"middle_name":null,"last_name":"HATZIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69294,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"EANNELLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152462,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
+3.12% NBIX
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in NBIX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Sold (partial) Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 17, 2025 · disclosed Aug 13, 2025 · Spouse · filed 57 days later
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Bought Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 11, 2025 · disclosed Aug 13, 2025 · Spouse · filed 63 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · filed 51 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · Spouse · filed 51 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.